Benzinga | Jul 26, 2021 09:39AM EDT

BeiGene's Brukinsa Scores Second Approval In Canada, This Time For Mantle Cell Lymphoma

* Health Canada has approved BeiGene Ltd (NASDAQ:BGNE) Brukinsa (zanubrutinib) for the treatment of mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy.

* This is the second approval for Brukinsa in Canada, following its initial approval in March for adult patients with Waldenstr?m's macroglobulinemia (WM).

* The Health Canada approval is based on efficacy results from two trials that achieved an overall response rate of 84%.

* Price Action: BGNE shares are trading lower by 6.75% at 295.57 on the last check Monday.

* Related content: Benzinga's Full FDA Calendar.